Feature | April 04, 2013

Cangrelor Superior to Clopidogrel in CHAMPION PHOENIX Trial

IV drug uniquely fast, reversible anti-clotting action has broad utility in cardiology

CHAMPION PHOENIX clinical study anti-platelet therapy cangrelor ACC 13

April 4, 2013 — The experimental anti-clotting drug cangrelor solidly outperformed commonly used clopidogrel in a large global trial of patients who underwent coronary stent procedures, according to data from the phase III CHAMPION PHOENIX clinical study presented at the American College of Cardiology’s 62nd Annual Scientific Session.

Cangrelor and clopidogrel interfere with the P2Y12 receptor, a platelet-surface protein that helps regulate blood clotting. Currently approved drugs in this class are effective in cutting down ischemic events — blood-flow reductions that can cause heart attack and stroke — in patients who need percutaneous coronary intervention (PCI), but they have important clinical limitations: they are slow to take effect, remain active for days and come only in pill form. For patients on recent anti-platelet therapy who need timely coronary intervention, that profile poses risk of surgical bleeding if the drug is still active or risk from postponing surgery until the drug’s effect wears off. Additionally, oral drugs present problems for anyone who urgently needs stenting and is in no condition to swallow or absorb a clot-preventing pill.

Cangrelor is administered intravenously, takes effect rapidly and wears off an hour after the infusion ends.

CHAMPION PHOENIX, a randomized double-blind trial, pitted the novel IV drug cangrelor against the oral clopidogrel standard of care in approximately 11,000 patients at 153 centers around the world. An “all-comers” clinical trial, it included a broad cross-section of patients with every type of acute coronary syndrome, angina and other conditions for which people undergo PCI, as long as they had no recent exposure to a P2Y12 inhibitor and could swallow a pill. Other exclusion criteria included recent use of anti-clotting agents called GP IIb/IIIa inhibitors or fibrinolytics and specific indications of high risk of bleeding.

Cangrelor performed significantly better than clopidogrel across efficacy measures: 4.7 percent vs. 5.9 percent, or a 22 percent reduction in the odds of the primary endpoint, which was composite incidence of death, myocardial infarction, ischemia-driven revascularization or stent thrombosis at 48 hours after randomization. Cangrelor also showed a 38 percent reduction in the odds of the key secondary endpoint, incidence of stent thrombosis at 48 hours. Both treatment arms showed a low, statistically comparable incidence for the safety endpoint of severe bleeding at 48 hours: 0.16 percent vs. 0.11 percent. The efficacy and safety results were consistent in all commonly reported subgroups.

“These are endpoints we worry about a lot in interventional cardiology and cardiology in general,” said Deepak L. Bhatt, M.D., MPH, chief of cardiology at VA Boston Healthcare System, senior physician at Brigham and Women’s Hospital, professor of medicine at Harvard Medical School, Boston and, along with Robert A. Harrington, M.D., chairman of medicine at Stanford University School of Medicine, co-principal investigator. “This study examined a very wide spectrum of patients, which means the results really do apply to a substantial percentage of patients undergoing stent procedures around the world.” The company plans to file for approval with the Food and Drug Administration using data from CHAMPION PHOENIX and the earlier BRIDGE trial.

“The investigators feel the data are compelling,” Bhatt explained. “The data we’ve shown are clear and consistent across all relevant subgroups or patient populations. This drug has several advantages, and nothing out there right now has quite the same biological properties.”

The Medicines Company sponsored the CHAMPION PHOENIX trial and provided a research grant to the Duke Clinical Research Institute for the statistical analyses and event adjudication.

This study was simultaneously published online in the New England Journal of Medicine (NEJM) at the time of presentation in March.

For more information: cardiosource.org

Related Content

News | Cath Lab| October 09, 2015
October 9, 2015 — Cardinal Health is launching its expanded portfolio in the cardiova
Shimadzu, MIX package, Trinias Cardiovascular suites, U.S. availability

Image courtesy of Shimadzu Medical Systems

Technology | Cath Lab| October 08, 2015
Shimadzu Medical Systems USA announced the availability of the MIX package for the Trinias Cardiovascular suites. Based...
ORSIF, radiation exposure for interventionalists, greater on left side of head, Ehtisham Mahmud
Feature | Radiation Dose Management| October 06, 2015
The results of a research study indicate that interventional cardiologists receive “very high” radiation exposure...
Synergy stent
Technology | October 05, 2015
October 5, 2015 — The U.S.
Tryton Side Branch Stent, clinical trial results, Catheterization and Cardiovascular Interventions

Tryton Side Branch Stent image courtesy of Tryton Medical

News | Stents Bifurcation| October 02, 2015
October 2, 2015 — Tryton Medical Inc.
Brilinta, 60 mg dose available, U.S. pharmacies
Technology | Antiplatelet and Anticoagulation Therapies| October 02, 2015
AstraZeneca announced that Brilinta (ticagrelor) 60-mg tablets are now available in U.S. pharmacies. On Sept. 3, 2015,...
Intact Vascular, TOBA II study, Tack Endovascular System

Image courtesy of Intact Vascular

News | Peripheral Arterial Disease (PAD)| October 01, 2015
Intact Vascular Inc. announced the U.S. Food and Drug Administration has granted conditional approval for a U.S. and...
Cook Medical, Zilver PTX, Japan PMS study, CIRSE 2015, two-year results

Image courtesy of Cook Medical

News | Stents Peripheral| October 01, 2015
Kimihiko Kichikawa, M.D., department of radiology at Nara Medical University in Japan, reported two-year results of the...
Stentys, CE Mark for self-apposing stent, lower limb artery disease, below-the-knee arteries, critical limb ischemia, PES BTK-70 trial

Image courtesy of Stentys

News | Stents Peripheral| October 01, 2015
Stentys announced that the company’s drug-eluting stent received CE Mark for treatment of below-the-knee (BTK) arteries...
raysafe, i2, staff dose monitoring
News | Radiation Dose Management| October 01, 2015
October 1,2015 — The first and only system that delivers real-time X-ray radiation dose monitoring for physicians and
Overlay Init